Clarivate (NYSE:CLVT) Insider Bar Veinstein Sells 254,558 Shares of Stock

Clarivate PLC (NYSE:CLVT – Get Free Report) insider Bar Veinstein sold 254,558 shares of the company’s stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $2.13, for a total transaction of $542,208.54. Following the completion of the transaction, the insider owned 1,008,458 shares in the company, valued at approximately $2,148,015.54. This represents a 20.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Clarivate Trading Down 2.0%

NYSE:CLVT opened at $2.01 on Friday. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -3.30 and a beta of 1.38. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.92. The company’s 50 day moving average price is $1.87 and its 200-day moving average price is $2.18. Clarivate PLC has a 52 week low of $1.42 and a 52 week high of $3.87.

Clarivate (NYSE:CLVT – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. The company had revenue of $481.60 million during the quarter, compared to analyst estimates of $566.77 million. Clarivate had a negative net margin of 17.02% and a positive return on equity of 9.84%. The firm’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.18 EPS. On average, equities research analysts forecast that Clarivate PLC will post 0.67 earnings per share for the current fiscal year.

Institutional Trading of Clarivate

Hedge funds have recently bought and sold shares of the company. FreeGulliver LLC purchased a new position in Clarivate in the first quarter worth about $30,000. Commonwealth Equity Services LLC bought a new stake in shares of Clarivate during the 3rd quarter valued at about $30,000. Headlands Technologies LLC bought a new stake in shares of Clarivate during the 3rd quarter valued at about $30,000. Principal Financial Group Inc. purchased a new stake in shares of Clarivate during the 1st quarter valued at about $32,000. Finally, Parallel Advisors LLC increased its position in shares of Clarivate by 94.2% during the 1st quarter. Parallel Advisors LLC now owns 13,786 shares of the company’s stock valued at $35,000 after purchasing an additional 6,687 shares during the last quarter. Hedge funds and other institutional investors own 85.72% of the company’s stock.

Analysts Set New Price Targets

CLVT has been the subject of several recent analyst reports. The Goldman Sachs Group decreased their price target on Clarivate from $2.60 to $2.30 and set a “neutral” rating for the company in a research note on Thursday, November 5th. Morgan Stanley initiated coverage on Clarivate in a research report on Friday, October 30th. They set an “underweight” rating and a $1.50 price objective on the stock. William Blair downgraded Clarivate to a “market perform” rating in a report on Thursday, October 15th. Citigroup reduced their price objective on Clarivate from $2.80 to $2.50 and set a “neutral” rating for the company in a report on Thursday, July 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research report on Monday, September 21st. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Clarivate currently has an average rating of “Reduce” and a consensus target price of $2.65.

Read Our Latest Analysis on CLVT

Clarivate Company Profile

(Get Free Report)

Clarivate provides information, analytics and workflow tools to customers in academia and government, life sciences and healthcare, and intellectual property. Its services help organizations find and analyze research, assess scientific and commercial developments, and manage patents, trademarks and other intellectual property. Its products include Web of Science and ProQuest research resources, Cortellis life sciences intelligence, and intellectual property databases and services such as Derwent.

Recommended Stories

Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.